ClinicalTrials.gg
RecruitingNCT07632755ADACTUpdated Jul 31, 2026

Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease

An interventional study of Control condition and Motor mental imagery in Alzheimer s Disease and Healhty, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 3 sites in France. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne — 3 open to participants now, 3 under way, none of them phase 3. Alzheimer Disease · Centre Hospitalier Universitaire de Saint Etienne.

Started
2026
with 2 others
No phase
8 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 11th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Centre Hospitalier Universitaire de Saint Etienne, or all of them as a file.
02

Study summary

In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.

Read the detailed description

In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.

03

Conditions studied

  • Alzheimer s Disease
  • Healhty

Browse trials for

Keywords

  • Alzheimer's disease
  • memory remediation
  • motor-enriched encoding
  • imagery
  • static imagery
  • dynamic imagery
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient group: Diagnosis of Alzheimer's disease made by one of the consulting physicians-a neurologist and/or geriatrician (Dubois et al., 2014)-at the early stage, presenting with mild memory impairment of which the patient has been informed

- score of 21 or higher

Control group: individuals without a diagnosis of Alzheimer's disease, but meeting the other criteria listed below

  • Enrollment in a social security program
  • Age 60 or older
  • French as a native language
  • Consent to participate

Exclusion criteria

Exclusion Criteria:

  • Uncorrected visual or hearing impairments
  • Language or motor impairments
  • Delirium or psychosis.
  • Medical treatment affecting vision, language, or motor skills (or participation in a study involving a drug or device that influences cognition).
  • Refusal to participate.
  • Inability to communicate
  • Persons deprived of liberty by a judicial or administrative decision and adults subject to a legal protection measure or unable to express their consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Control condition

    Control condition

    Behavioral: Control condition

  • Experimental
    Motor imagery intervention

    Motor imagery intervention

    Behavioral: Motor mental imagery

  • Experimental
    Real action

    Real action

    Behavioral: Action execution

Interventions

  • BehavioralControl condition

    Reading a sentence aloud and the participant is asked to freely recall, without delay and without cues, all the sentences presented in the block. The number of correctly recalled sentences is recorded.

    Also known as: A

  • BehavioralMotor mental imagery

    Following the reading of each sentence, the participant is instructed to mentally simulate performing the action described in the sentence. And the participant is asked to freely recall, without delay and without cues, all the sentences presented in the block. The number of correctly recalled sentences is recorded.

    Also known as: B

  • BehavioralAction execution

    After reading the sentence, the participant pantomimes the action described and The participant is asked to freely recall, without delay and without cues, all the sentences presented in the block. The number of correctly recalled sentences is recorded.

    Also known as: C

06

What researchers measure

Primary outcomes

  1. Free recall score

    The free recall score corresponds to the number of sentences spontaneously retrieved by participants after learning, measuring free retrieval ability.

    Time frame: at 1 week

07

Study locations

1 of 3 sites recruiting
  • Chu Grenoble
    Grenoble, 38700, France
    Not yet recruiting
    • Mathilde SAUVEE, MD · Principal investigator
    • Olivier MOREAUD, MD · Sub investigator
  • Chu de Saint Etienne
    Saint-Etienne, 42055, France
    Recruiting
    • Céline BORG, MD · Principal investigator
  • HLC, Hôpital des Charpennes
    Villeurbanne, 69100, France
    Not yet recruiting
    • Isabelle ROUCH, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — insitute decision

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 20 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 8, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jun 2028
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632755
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Jul 15, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 31, 2026

Study contacts

Céline BORD, MD
Contact
celine.borg@chu-st-etienne.fr
(0)4 77 82 88 82 ext. +33
Céline LECLERCQ TRAUTVETTER, CDP
Contact
Celine.LECLERCQTRAUTVETTER@chu-stetienne.fr
(0)4 77 82 94 27 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion